
In connection with Novo Nordisk’s first quarterly report Friday morning, the company has announced that the contract manufacturer in charge of filling Wegovy doses, an obesity treatment currently available in the US, has reinitiated its commercial production.
The subsupplier had run into issues in the past, which strained the overall production plans for Wegovy.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app